MHRA
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

gov.uk/mhra

Decision Cover Letter

Decision of the licensing authority to:

accept change(s) to the agreed paediatric investigation plan (EMEA-001877-PIP01-15-M02) and to the deferral

MHRA-101375-PIP01-24-M01

Scope of the Application

Active Substance(s)

FREMANEZUMAB

Condition(s)

Prophylaxis of migraine headaches

Pharmaceutical Form(s)

Solution for injection

Route(s) of Administration

SUBCUTANEOUS USE

Name / Corporate name of the PIP applicant

Teva UK Limited

Basis for the Decision

Pursuant to the Human Medicines Regulations 2012, Teva UK Limited submitted to the licensing authority on 23/02/2024 08:30 GMT an application for a Modification

The procedure started on 08/04/2024 07:05 BST

1. The licensing authority, having assessed the application in accordance with the Human Medicines Regulations 2012, decides, as set out in the appended summary report:

to accept change(s) to the agreed paediatric investigation plan and to the deferral

2. The measures and timelines of the paediatric investigation plan are set out in the Annex I.

This decision is forwarded to the applicant, together with its annex and appendix.

MHRA
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

gov.uk/mhra

Final Decision Letter

MHRA-101375-PIP01-24-M01

Of 24/06/2024 08:22 BST

On the adopted decision for FREMANEZUMAB (MHRA-101375-PIP01-24-M01) in accordance with the Human Medicines Regulations 2012.

The licensing authority, in accordance with the Human Medicines Regulations 2012, has adopted this decision:

Agreement on modification of a paediatric investigation plan (including modification of a waiver or deferral included in that paediatric investigation plan)

This decision applies to a Modification for FREMANEZUMAB, Solution for injection , SUBCUTANEOUS USE .

This decision is addressed to Teva UK Limited, Field house, Station Approach, Harlow, UNITED KINGDOM, CM20 2FB

ANNEX I

1. Waiver

1.1 Condition:

Prevention of migraine headaches The waiver applies / applied to: Paediatric Subset(s): The paediatric population from birth to less than 6 years years of age Pharmaceutical form(s): Solution for injection Route(s) of administration: SUBCUTANEOUS USE Reason for granting waiver: on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments.

2. Paediatric Investigation Plan:

2.1 Condition(s):

Prevention of migraine headaches

2.2 Indication(s) targeted by the PIP:

Prophylaxis of headache in children aged 6 to less than 18 years with episodic and chronic migraine

2.3 Subset(s) of the paediatric population concerned by the paediatric development:

The paediatric population from 6 years to less than 18 years of age

2.4 Pharmaceutical Form(s):

Solution for injection

2.5 Studies:

Study Type	Number of Studies	Study Description
Quality Measures	0	Not applicable.
Non-Clinical Studies	2	Study 1 Reproductive toxicity and post-natal development study. Study 2 Definitive juvenile toxicity study.
Clinical Studies	4	Study 3 (TV48125-CNS-10141) Pharmacokinetic and safety study in paediatric patients from 6 years to less than 12 years of age following a single subcutaneous dose of fremanezumab. Study 4 (TV48125-CNS-30083) Efficacy and safety, placebo controlled study of fremanezumab in paediatric patients from 6 years to less than 18 years of age with episodic migraine (EM). Study 5 (TV48125-CNS-30082) Efficacy and safety, placebo controlled study of fremanezumab in paediatric patients from 6 years to less than 18 years of age with Chronic Migraine (CM). Study 6 (TV48125-CNS-30084) Long-term, safety, tolerability and efficacy open-label single arm study of fremanezumab in paediatric patients from 6 years to less than 18 years of age with history of migraine (CM or EM) who participated to Study 4 and 5.

Extrapolation, Modeling & Simulation Studies	3	Study 7 (CP-18-03) Modelling and simulation dose-finding study based on a one compartment model with allometric weight scaling with data from adult healthy volunteers and patients with EM and CM. Study 8 (CP-18-05) Modelling and simulation dose-finding study based on a two compartment model with allometric weight scaling with data from paediatric pharmacokinetic study 3. Study 9 Modelling and simulation inferential study including a comprehensive evaluation of the effect of covariates on PK and exposure-response parameters pooling all available paediatric and adult data.
Other Studies	0	Not applicable.
Other Measures	0	Not applicable.

3. Follow-up, completion and deferral of a PIP:

Concerns on potential long term safety and efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	31/12/2027
Deferral of one or more studies contained in the paediatric investigation plan:	Yes